WebDec 6, 2024 · SEOUL, South Korea, Dec. 6, 2024 /PRNewswire/ -- Recently, Selecxine, a partner of GenScript ProBio, announced MFDS clearance of its phase I/II clinical trial application for innovative antibody drug program (SLC-3010) . GenScript ProBio extended congratulations on this. Since December 2024, GenScript ProBio has joined the strategic … WebDec 26, 2024 · Data & APIs. Events. Marketfy
Fugit Township, Decatur County, Indiana - Wikipedia
WebSelecxine is a South Korean biotech that specializes in developing therapeutical antibodies. Founded in December 2024, Selecxine is now in clinical trial with its lead asset and keep developing follow-up pipelines with their in-house antibody development technology. Based on understanding of cancer immunology and structural biology, Selecxine ... WebPresently, Jun-Young Lee is Chief Executive Officer of Selecxine, Inc. Co Ltd. Mr. Lee is also Vice President & Head-Visual Display Purchasing at Samsung Electronics Co., Ltd. He received an undergraduate degree from Soongsil University. Current positions of Jun-Young Lee Jun-Young Lee: Personal Network 03/03 bitsbox.com
GenScript ProBio LinkedIn
WebJun 30, 2024 · Selecxine is a biotech company that develops therapeutics for immuno-oncology. The company develops monoclonal antibodies that bind to specific epitope on … WebSelecxine Founded in 2024 "Selecxine strives to develop immunotherapeutics – a new paradigm of pharmaceuticals– through a specialized antibody development process, … WebSelecxine is a biopharmaceutical development company specialized in the field of immunotherapeutics. Selecxine strives to develop immunotherapeutics – a new paradigm … Selecxine’s unique antibody platform technology Development of specific functio… bitsbox blueprint